A Phase 1/2 Trial of Bleximenib for Acute Leukemia
Phase 1/2
400
about 7 years
2+
27 sites in AZ, CA, IL +14
What this study is about
This trial is testing a treatment called bleximenib in people with acute leukemia. The goal is to find the best dose that's safe and effective, and then evaluate how well it works at that dose.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Bleximenib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor
Primary: Phase 1: Number of Participants with AEs by Severity, Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability, Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT), Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)
Secondary: Phase 1 and 2: Overall Response Rate (ORR), Phase 1: Duration of Response (DOR), Phase 2: Duration of Complete Response (CR)/Complete Remission With Partial Hematologic Recovery (CRh), Phase 2: Event-free survival (EFS), Phase 2: Measurable Residual Disease (MRD) Negativity Among Participants Achieving CR/CRh/CRi, Phase 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 2: Overall survival (OS), Phase 2: Time To CR/CRh
Oncology